Tom Stefan

“I'll just keep it to one in the interest of time. But Brent, can you maybe talk a little bit more about the update on Invista Beyond from the press release? What's kind of the likely path forward here for the product?”

“So, Ron, maybe for you, is there anything RxCite can do or is there anything specific you're exploring to, I guess, perhaps manage these trialing headwinds moving forward?”

“First one on tier care, I know it's early and this may be a difficult question, but as coverage and reimbursement starts to take hold, can you talk to us a bit about sort of how you think about the peak sales potential of tier care, the inputs, the framework, et et cetera.”

“And then just my follow-up, more thematic and taking a step back, Warren or Deborah, maybe if you can spend some time just discussing sort of the health of the organization today and how it compares to pre-Alcon.”